1. Scrip
  2. >>Therapy Areas

'Breakthrough' status granted to Aimmune's peanut allergy drug

 
• By Donna Young

The FDA has granted breakthrough therapy designation (BTD) to Aimmune Therapeutics' investigational oral immunotherapy for peanut allergy, known as AR101.

The FDA has granted breakthrough therapy designation (BTD) to Aimmune Therapeutics' investigational oral immunotherapy for peanut allergy, known as AR101.

Brisbane, California-based Aimmune said its drug, which is intended for children and adolescents 4-17 years, is a highly characterized, complex mixture of naturally occurring proteins and pharmaceutical-grade inactive ingredients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.